Mark J. Ratain to Genetic Variation
This is a "connection" page, showing publications Mark J. Ratain has written about Genetic Variation.
Connection Strength
1.016
-
Challenges in interpreting the evidence for genetic predictors of ototoxicity. Clin Pharmacol Ther. 2013 Dec; 94(6):631-5.
Score: 0.290
-
A survey of the population genetic variation in the human kinome. J Hum Genet. 2009 Aug; 54(8):488-92.
Score: 0.215
-
Interpreting disparate responses to cancer therapy: the role of human population genetics. J Clin Oncol. 2006 May 10; 24(14):2151-7.
Score: 0.172
-
Single nucleotide polymorphism discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 gene. Pharmacogenet Genomics. 2008 Aug; 18(8):683-97.
Score: 0.050
-
Global gene expression as a function of germline genetic variation. Hum Mol Genet. 2005 Jun 15; 14(12):1621-9.
Score: 0.040
-
UGT pharmacogenomics: implications for cancer risk and cancer therapeutics. Pharmacogenetics. 2003 Aug; 13(8):517-23.
Score: 0.035
-
Screening for sources of interindividual pharmacokinetic variability in anticancer drug therapy: utility of population analysis. Cancer Invest. 2001; 19(1):57-64.
Score: 0.030
-
A New Liver Expression Quantitative Trait Locus Map From 1,183 Individuals Provides Evidence for Novel Expression Quantitative Trait Loci of Drug Response, Metabolic, and Sex-Biased Phenotypes. Clin Pharmacol Ther. 2020 06; 107(6):1383-1393.
Score: 0.028
-
Genomic Heterogeneity Within Individual Prostate Cancer Foci Impacts Predictive Biomarkers of Targeted Therapy. Eur Urol Focus. 2019 05; 5(3):416-424.
Score: 0.024
-
UGT1A and UGT2B genetic variation alters nicotine and nitrosamine glucuronidation in european and african american smokers. Cancer Epidemiol Biomarkers Prev. 2015 Jan; 24(1):94-104.
Score: 0.019
-
Establishment of CYP2D6 reference samples by multiple validated genotyping platforms. Pharmacogenomics J. 2014 Dec; 14(6):564-72.
Score: 0.019
-
Genetic factors affecting gene transcription and catalytic activity of UDP-glucuronosyltransferases in human liver. Hum Mol Genet. 2014 Oct 15; 23(20):5558-69.
Score: 0.019
-
A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469. Pharmacogenet Genomics. 2014 Feb; 24(2):129-32.
Score: 0.018
-
Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751. Pharmacogenet Genomics. 2013 Jul; 23(7):374-81.
Score: 0.018
-
Pharmacogenomics and patient care: one size does not fit all. Sci Transl Med. 2012 Sep 26; 4(153):153ps18.
Score: 0.017
-
Creating and evaluating genetic tests predictive of drug response. Nat Rev Drug Discov. 2008 07; 7(7):568-74.
Score: 0.012
-
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol. 2004 Apr 15; 22(8):1382-8.
Score: 0.009